Among 50 early-stage HCC patients, the panel showed 72.0% (95% CI 57.7–83.4%) sensitivity, while AFP alone showed a sensitivity of only 48.0% (95% CI 33.7–62.6%), and DCP alone showed a sensitivity of 62.0% (95% CI 46.2–74.6%) (Table 3). Here, ACE is linked to hepatocellular carcinoma.